Cargando…
Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
BACKGROUND: The genomic and overall biologic landscape of glioblastoma (GB) has become clearer over the past 2 decades, as predictive and prognostic biomarkers of both de novo and transformed forms of GB have been identified. The oral chemotherapeutic agent temozolomide (TMZ) has been integral to st...
Autores principales: | Pandey, Manjari, Xiu, Joanne, Mittal, Sandeep, Zeng, Jia, Saul, Michelle, Kesari, Santosh, Azadi, Amir, Newton, Herbert, Deniz, Karina, Ladner, Katherine, Sumrall, Ashley, Korn, W Michael, Lou, Emil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270729/ https://www.ncbi.nlm.nih.gov/pubmed/35821680 http://dx.doi.org/10.1093/noajnl/vdac096 |
Ejemplares similares
-
Primary CNS lymphoma commonly expresses immune response biomarkers
por: Ou, Alexander, et al.
Publicado: (2020) -
Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling
por: Dardis, Christopher, et al.
Publicado: (2021) -
Correction to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling
por: Dardis, Christopher, et al.
Publicado: (2021) -
Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?
por: Carrillo, Jose A., et al.
Publicado: (2019) -
Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts
por: Almstedt, Elin, et al.
Publicado: (2021)